Skip to content
HeyJared

Overlooked Alpha

Overlooked Alpha uncovers under-the-radar stocks and misunderstood investment opportunities. Over 250 stocks covered.

Newsletter · By Overlooked Alpha · English · Paid tier available · Official site

Indexed issues, last 90 days
3
Latest publication
Sep 25, 2026
Audience
Checking…
Earliest in this view
Jul 27, 2026

Latest issues

  1. Issue · Sep 25, 2026

    A 30% Margin Business Priced for Almost No Growth (opens the original)

    Excerpt

    Read excerpt

    Good morning,Today I’m pitching a founder-led small cap that the market has decided is broken.The company fell 18% on Tuesday after H1 results showed slowing organic growth, weak cash conversion and rising debt to fund acquisitions. These concerns are real, and I address each of them below. But today’s price assumes something much harsher than the results show. After stripping out management’s adjustments and deducting the real cost of employee incentives, I estimate the market is paying under 1

  2. Issue · Aug 17, 2026

    Profits Just Grew 642% And The Stock Still Looks Cheap (opens the original)

    Excerpt

    Read excerpt

    Good morning, Today we are covering a small Japanese platform business showing signs of a major earnings inflection.Paying users are up 54%, gross merchandise value is up 50% and operating profit has surged 642%.Management has responded by more than doubling full-year profit guidance. Yet despite improving fundamentals, the business is still valued at under 10x this year’s operating profit. The question is whether this is a temporary spike or the start of something more durable.Let’s take a clos

  3. Issue · Jul 27, 2026

    Record Results Can Propel This Software Small Cap (opens the original)

    Excerpt · Positive tone

    Read excerpt

    Today we are publishing on a small UK software company that may be approaching an important inflection point. In results released last week, organic ARR growth accelerated to approximately 23%, and recurring revenue climbed to 81% of total sales. The company also secured a strategically important US order from a leading medical-device manufacturer, with scope to expand into additional sites.With a debt-free balance sheet, embedded products and significant scope for margin expansion, we think thi

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

No verified audience measurement yet.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Overlooked Alpha